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Abstract 65 
Context: 66 
Maternal gestational diabetes (GDM) and pre-pregnancy overweight/obesity (body mass 67 
index, BMI ≥25kg/m2) may adversely affect offspring cardio-metabolic health. 68 
Objective: 69 
To assess associations of maternal GDM and pre-pregnancy overweight/obesity with adult 70 
offspring cardio-metabolic risk factors. 71 
Design: 72 
Longitudinal cohort study (ESTER and AYLS). 73 
Setting: 74 
Province of Uusimaa and Northern Finland. 75 
Participants: 76 
At mean age 24.1 years (SD 1.3), we classified offspring to offspring of mothers with 1) GDM 77 
regardless of pre-pregnancy BMI (OGDM; n=193), 2) normoglycemic mothers with pre-78 
pregnancy overweight/obesity (ONO, n=157) and 3) normoglycemic mothers with pre-79 
pregnancy BMI<25kg/m2 (controls, n=556). 80 
Main Outcome Measures: 81 
We assessed cardio-metabolic biomarkers from blood and measured resting blood pressure 82 
and heart rate. 83 
Results: 84 
Compared with controls, OGDM and ONO had higher fasting glucose [1.6% (95% confidence 85 
interval 0.1, 3.1)]; [2.3% (0.5, 4.3), respectively]; and insulin [12.7% (4.4, 21.9)]; [8.7% (0.2, 86 
17.8)]. These differences attenuated to non-significance when adjusted for confounders 87 
and/or current offspring characteristics including BMI or body fat percentage. OGDM 88 
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showed lower sex hormone binding globulin [SHBG; men: -12.4% (-20.2, -3.9), women: -89 
33.2% (-46.3, -16.8)], high-density lipoprotein [-6.6% (-10.9, -2.2)] and apolipoprotein A1 [-90 
4.5% (-7.5, -1.4), these differences survived the aforementioned adjustments. Heart rate 91 
and other biomarkers were similar between groups. 92 
Conclusions: 93 
Adult offspring of mothers with GDM have increased markers of insulin resistance and a 94 
more atherogenic lipid profile; these are only partly explained by confounders or current 95 
offspring adiposity. Maternal pre-pregnancy overweight/obesity is associated with impaired 96 
offspring glucose regulation, which is explained by confounders and/or current adiposity. 97 
  98 
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Précis 99 
We measured cardio-metabolic markers in offspring of mothers with GDM, pre-pregnancy 100 
overweight and controls. GDM was, unlike maternal overweight, linked with an unhealthier 101 
cardio-metabolic profile. 102 
  103 
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Introduction 104 
Metabolic abnormalities, including alterations in lipid and carbohydrate metabolism, are 105 
likely among women with gestational diabetes (GDM), overweight (body mass index, BMI ≥ 106 
25kg/m2) or obesity (BMI ≥ 30kg/m2) during pregnancy. At a critical period of fetal 107 
development, exposure to e.g. hyperglycemia, may induce long-term impacts on the fetus 108 
by creating a metabolic memory, previously described as fetal programming (1). Prenatal 109 
exposure to a hyperglycemic environment is known to alter growth trajectories and 110 
homeostatic regulatory mechanisms, and these changes predispose offspring to epigenetic 111 
changes (2, 3). It is likely that both maternal GDM and overweight/obesity provide a 112 
prenatal environment making the fetus susceptible to adverse in utero programming. This 113 
may cause increased risk of next-generation overweight and obesity, and result in an 114 
intergenerational cycle of obesity and insulin resistance. 115 
Offspring of mothers with GDM show markers of insulin resistance and metabolic 116 
syndrome, higher BMI and waist circumference by adolescence (4). Further, adult offspring 117 
of mothers with GDM represent a risk group for overweight and metabolic syndrome (5). 118 
Exposure to maternal obesity during pregnancy also affects offspring health, particularly 119 
with increased risk for obesity and metabolic sequelae (6). In a recent review by Nicholas et 120 
al. maternal obesity increased offspring risk of both obesity and insulin resistance in 121 
childhood, adolescence and adulthood (7). Previous studies have also linked high maternal 122 
pre-pregnancy BMI to unfavorable offspring body composition in infancy (8), childhood (9), 123 
adolescence (10) and young adulthood (11). Even at a mean age of 62 years a less favorable 124 
body composition and higher BMI in the offspring has been reported (12). However, it is not 125 
always clear to what extent the associations represent genetic or lifestyle factors, shared by 126 
the family, and to what extent they represent causal programming effects. Moreover, it is 127 
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uncertain to what extent these offspring consequences are a result of exposure to maternal 128 
GDM and to what extent maternal overweight/obesity. 129 
Despite previously well-established data on the strong influence of maternal pre-pregnancy 130 
overweight/obesity or GDM on offspring’s increased risk for obesity and metabolic sequelae 131 
during childhood, it is less clear whether the effects extend into adult age. 132 
Taking these observations together, we hypothesized that maternal GDM and pre-133 
pregnancy overweight/obesity may affect cardio-metabolic risk factors in adult offspring. In 134 
this study, we investigate the impact of exposure to maternal GDM or pre-pregnancy 135 
overweight/obesity on adult offspring cardio-metabolic health. 136 
 137 
Materials and Methods 138 
Participants 139 
Participants of the current study come from two prospective birth cohorts (Figure 1) (11): 140 
the ESTER Maternal Pregnancy Disorders Study and the Arvo Ylppö Longitudinal Study 141 
(AYLS). 142 
The ESTER Study consists of two arms (Figure 1): 1) ESTER Preterm Birth (13) and 2) ESTER 143 
Maternal Pregnancy Disorders arms. The present study is based on the latter arm. All ESTER 144 
study participants were born in the two northernmost provinces of Finland. Those born in 145 
1985–1986 were recruited from the Northern Finland Birth Cohort 1986 (NFBC 1986) (14) 146 
and those born in 1987–1989 through the Finnish Medical Birth Register (FMBR) (13), as 147 
previously described (15). We selected all participants of the ESTER Maternal Pregnancy 148 
Disorders arm who were confirmed to have maternal GDM (n=157), regardless of the 149 
mother’s pre-pregnancy BMI. Among ESTER clinical study participants invited as controls 150 
(15), participants were stratified into two groups: one group with maternal pre-pregnancy 151 
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overweight/obesity included offspring born at term to mothers with pre-pregnancy BMI ≥ 152 
25kg/m2 and no GDM (n=44), while the control group constituted the remaining controls, all 153 
with maternal pre-pregnancy BMI < 25kg/m2 and no GDM (n=281). 154 
All AYLS participants (Figure 1) were born in the province of Uusimaa, in Southern Finland 155 
between 1985 and 1986. This cohort consists of all live-born infants admitted to neonatal 156 
wards in obstetric units, or transferred to the neonatal intensive care unit of the Children’s 157 
Hospital, Helsinki University Central Hospital within 10 days of their birth, with the 158 
population ranging from severely ill preterm infants to infants born at term, requiring only 159 
brief inpatient observation, and their controls, as previously described (16, 17). Of these 160 
AYLS cohort participants, with data available, we selected 1) all who were exposed to 161 
maternal GDM, at any maternal BMI (n=37), 2) those who had maternal BMI ≥ 25kg/m2 and 162 
no GDM (n=109) and 3) controls (i.e. originally recruited as controls, maternal BMI < 163 
25kg/m2 and no GDM; n=266). 164 
For all study participants, perinatal data were collected from healthcare records and 165 
questionnaires. Length of gestation, maternal GDM, hypertension (gestational or chronic) 166 
and preeclampsia (including superimposed) diagnoses were independently confirmed 167 
according to prevailing criteria by reviewing original hospital records (4, 18). Maternal GDM 168 
was screened for and diagnosed by oral glucose tolerance test (OGTT). Screening was 169 
performed in the maternal welfare clinics between 26 and 28 gestational weeks. Indications 170 
for screening were glucosuria, prior GDM, suspected fetal macrosomia, previous 171 
macrosomic infant (birth weight >4,500 g), maternal pre-pregnancy BMI ≥ 25 kg/m2, and 172 
maternal age ≥ 40 years. The OGTT was performed after overnight fasting by using a 75-g 173 
oral glucose load. At the time of diagnosis in the 1980s, the following cutoff limits for GDM 174 
were used for venous blood glucose: >5.5 mmol/l at fasting, >11.0 mmol/l and >8.0 mmol/l, 175 
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1 hour and 2 hours after the glucose load, respectively. According to prevailing national 176 
guidelines, a diagnosis of GDM required a minimum of one abnormal value in the OGTT (4). 177 
For comparison, the International Association of Diabetes and Pregnancy Study Groups 178 
(IADPSG) Consensus Panel diagnostic criteria used today are set at fasting plasma glucose 179 
≥5.1mmol/l, and ≥10.0 mmol/l and ≥8.5 mmol/l following a 75g oral glucose load (19). 180 
Offspring to mothers with type 1 (n=28) or 2 diabetes (n=1) were excluded from all analyses. 181 
We further excluded subjects who were pregnant (n=9) during the clinical examination, 182 
reported having cerebral palsy (n=8), mental disability (n=11) or severe physical disability 183 
(n=5), as these conditions might affect the measured outcomes. We categorized all ESTER 184 
and AYLS cohort participants who underwent biochemical measures into three groups: 1) 185 
offspring of mothers with GDM (OGDM) at any level of maternal BMI, 2) offspring of 186 
normoglycemic mothers with pre-pregnancy overweight/obesity (ONO) and 3) controls, i.e. 187 
offspring of mothers with pre-pregnancy BMI < 25kg/m2 and no GDM. As a result, 906 188 
subjects were included in the analyses; OGDM n = 193, ONO n= 157 and 556 controls. 189 
 190 
Ethics 191 
Our study protocol was in accordance with the Declaration of Helsinki. It was approved by 192 
the Ethics Committees of the University of Oulu, the Helsinki City Maternity Hospital, the 193 
Helsinki University Central Hospital and Jorvi Hospital, the Ethics Committee of the Northern 194 
Ostrobothnia Hospital District and the Coordinating Ethics Committee of the Helsinki and 195 
Uusimaa Hospital District. Written informed consent was obtained from all participants. 196 
Because of individual participant consent, these data are not freely available. Researchers 197 
requesting data access are asked to contact the corresponding author. Requests may be 198 
subject to ethics review and/or participant’s re-consent. 199 
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 200 
Measures and procedures 201 
Anthropometry was measured during clinical examinations conducted in 2009-2011 for 202 
ESTER participants and during 2009-2012 for AYLS participants. Height was measured three 203 
times without socks and shoes, with a portable stadiometer. Weight was measured during 204 
the clinical visit. Most of our participants also underwent bioimpedance measurement and 205 
the bioimpedance devise (InBody 3.0, Biospace Co., Ltd., Seoul, Korea) contains a scale. For 206 
individuals who did not undergo bioimpedance we used an electronic scale. BMI was 207 
calculated using means of the repeated measurements [weight (kg) / height squared (m2)]. 208 
All participants attended a clinical visit in the morning, after an overnight fast. They were 209 
examined by a trained study nurse. After a 5-minute rest in a sitting position, blood pressure 210 
was measured 3 times from the right upper arm using an automatic oscillometric blood 211 
pressure monitor (Omron M10-IT Intellisense, Omron Healthcare Co., Kyoto, Japan). All 212 
participants completed questionnaires regarding both participant and parental health 213 
status, including medical history and medications. Data on highest parental educational 214 
attainment were enquired and categorized into four levels (dummy coded) to serve as an 215 
indicator of childhood socioeconomic status. 216 
 217 
Laboratory analyses  218 
At the clinical visit venous blood samples were taken in a sitting position with a light stasis 219 
into a fluoride-citrate tube (Venosafe, Terumo Europa, Leuven, Belgium) for glucose assays 220 
and into a tube containing clot activator (Venosafe) for other assays. Fluoride-citrate plasma 221 
and serum were separated by centrifuging, frozen locally immediately after separation, and 222 
then transported frozen on dry ice to the biochemistry laboratory of the Genomics and 223 
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Biomarker Unit (former the Disease Risk Unit) at National Institute for Health and Welfare 224 
(Helsinki, Finland) and the Oulu University Hospital laboratory. All analyses were performed 225 
on a clinical chemistry analyzer (Architect ci8200 Abbott Laboratories, Abbott Park, Illinois, 226 
USA) at the biochemistry laboratory in the AYLS and ESTER studies, except for fasting plasma 227 
glucose, total cholesterol (TC), high- and low-density lipoprotein cholesterol (HDL-C and LDL-228 
C), triglycerides (TGs), alanine aminotransferase (ALT), aspartate transaminase (AST), 229 
gamma glutamate (GT) and uric acid regarding ESTER study participants. In the ESTER study 230 
these samples were analyzed by using an Advia 2400 automatic chemical analyzer (Siemens 231 
Diagnostics, Terrytown, NY, USA) at Oulu University Hospital laboratory, and have been 232 
described in detail previously (13) (freely available as web appendix). 233 
For standardizing measurements, the biochemistry laboratory has taken part in Lipid 234 
Standardization Program organized by Centers for Disease Control and Prevention (CDC, 235 
Atlanta, Georgia, USA) and External Quality Assessment Schemes organized by Labquality 236 
(Helsinki, Finland). During the course of the studies, the between-assay coefficient of 237 
variation (CV%, mean ±SD), systematic error (Bias%, mean ±SD) and the principle of the 238 
methods in the biochemistry laboratory are shown in Supplementary Table 1 (20). 239 
 240 
Statistical analyses 241 
All statistical analyses were conducted with IBM SPSS Statistics versions 24 and 25 (SPSS 242 
Inc., Chicago, IL, USA). Analyses were performed in a combined dataset of both birth cohorts 243 
(ESTER and AYLS). We compared descriptive characteristics between participants with t-test 244 
(continuous variables) and χ2-test (categorical variables). The significance level was set to 245 
two-tailed P < 0.05. As the biochemical measures were not normally distributed, we log-246 
transformed them prior to statistical analyses, to attain normality. We used multiple linear 247 
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regression models to compare cardio-metabolic biochemical measures, blood pressure and 248 
heart rate between adult offspring of mothers with GDM or pre-pregnancy 249 
overweight/obesity with controls. We adjusted for age, sex and birth cohort in model 1. 250 
Prenatal and parental confounders were taken into account in model 2, as we additionally 251 
adjusted for gestational age, birth weight SD score, maternal hypertension or preeclampsia 252 
during pregnancy, maternal smoking during pregnancy, parental educational attainment, 253 
parental history of hypertension, diabetes, stroke or myocardial infarction. Participant 254 
related factors, including age, sex, birth cohort, BMI, height and daily smoking were 255 
adjusted for in model 3. Finally, in the full model 4, all the above mentioned covariates were 256 
included. 257 
 258 
Results 259 
Perinatal and current characteristics and parental medical history of the OGDM, ONO and 260 
control groups are presented in Table 1. For comparison, these data are also shown 261 
separately for the two source cohorts in Supplementary Table 2 (20). Mean age of offspring 262 
at assessment was 24.1 years (SD 1.3) and 51.3 % were women. Among offspring, 2 OGDM, 263 
2 ONO and 8 controls were born from twin pregnancies, the remainder were all singletons. 264 
As a sensitivity analysis, we excluded all twins and reran all analyses. This did not affect our 265 
results. Cardio-metabolic biochemical measures, heart rate and blood pressure of the 266 
offspring, with corresponding reference or target values are presented in Table 2. 267 
 268 
Cardio-metabolic markers in offspring of mothers with gestational diabetes (Table 3) 269 
There were clear associations between maternal GDM and adult offspring cardio-metabolic 270 
markers. Fasting glucose and insulin were higher in OGDM compared with controls, 271 
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although adjusting for confounders and current offspring characteristics including BMI 272 
attenuated these differences to non-significance (Table 3, Supplementary Table 3) (20). 273 
Further, OGDM had lower sex hormone binding globulin (SHBG) in both OGDM-men and 274 
OGDM-women. Also HDL-C, Lipoprotein (a) (Lp(a)) and Apolipoprotein A1 (ApoA1) were 275 
lower; apart from Lp(a), these differences survived adjustment for confounders and current 276 
characteristics. No statistically significant differences were seen in heart rate, testosterone, 277 
LDL-C, TGs, Apolipoprotein B (ApoB), free fatty acid (FFA), uric acid or liver tests (ALT, AST, 278 
GT). In model 1, TC and blood pressure was similar between OGDM and controls, while after 279 
adjusting for confounders and current characteristics TC, systolic and diastolic blood 280 
pressures were slightly lower in OGDM (Table 3, Supplementary Table 3) (20).  281 
We further reran all analyses, replacing BMI and height with lean body mass and fat 282 
percentage in models 3 and 4 (data not shown). The results remained similar for model 3. In 283 
model 4, our findings of lower FFA [-9.2% ((-17.6, -0.1)] and hsCRP [-23.2 (-40.3, -1.1)] in 284 
OGDM both reached statistical significance. 285 
To further distinguish between effects of maternal GDM and maternal overweight/obesity 286 
on adult offspring cardiovascular risk factors, we reran all analyses separately comparing 287 
offspring to mothers with 1) GDM and pre-pregnancy BMI < 25kg/m2 (n=115) 2) GDM and 288 
pre-pregnancy BMI ≥ 25kg/m2 (n=71) with controls (n=556). Most of our results remained 289 
similar (Supplementary Table 4) (20). A combination of maternal GDM and 290 
overweight/obesity showed a greater effect on fasting glucose and insulin than maternal 291 
overweight/obesity alone. Adjusting for confounders attenuated these differences between 292 
groups and this was largely due to offspring BMI as a mediator in OGDM with maternal BMI 293 
≥ 25 kg/m2. 294 
 295 
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Cardio-metabolic markers in offspring of mothers with overweight/obesity (Table 3) 296 
Associations found between maternal pre-pregnancy overweight/obesity and adult 297 
offspring cardio-metabolic markers were mostly explained by current offspring 298 
characteristics and confounders. Fasting glucose and insulin were both higher in ONO vs. 299 
controls, these findings disappeared after adjustments in models 2-4 (Table 3, 300 
Supplementary Table 3) (20). In men, serum testosterone was lower in model 1, also this 301 
difference attenuated after adjustments in models 2-4. All other cardio-metabolic markers, 302 
including heart rate, SHBG, FFA, TC, HDL-C, LDL-C, TGs, LPa, ApoA1, ApoB, liver tests and uric 303 
acid were similar between ONO and controls. Only in model 2, hsCRP was higher in the ONO 304 
group, adjustment for confounders diluted this finding. However, although systolic blood 305 
pressure was not different between groups in model 1, it was somewhat lower in models 2-306 
4 in ONO-participants (Table 3, Supplementary Table 3) (20).  307 
As with OGDM, we also reran all analyses comparing ONO vs. controls, replacing BMI and 308 
height with lean body mass and fat percentage in models 3 and 4. No changes were seen in 309 
the results (data not shown). 310 
We further reran all analyses separately comparing offspring to mothers with pre-pregnancy 311 
BMI ≥ 30kg/m2 (n=28) vs. controls. Most results remained similar (data not shown). 312 
However, in model 1, hsCRP [66.2% (95% CI. 3.6, 166.3)], TGs [21.5% (95% CI: 2.3, 44.3)] and 313 
ApoB [10.8% (95% CI: 0.1, 22.7)] were all higher in in offspring exposed to maternal pre-314 
pregnancy obesity compared with controls. Further, in model 1, heart rate was lower [-5.5% 315 
(95%CI: -10.0, -1.0)] and fasting plasma glucose similar [-1.3% (95% CI:-4.3, 1.7)] between 316 
obesity exposed and controls. After full adjustment (model 4) all results were similar with 317 
ONO vs. controls regarding all cardio-metabolic markers (data not shown). 318 
 319 
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Discussion 320 
We combined data from two longitudinal birth cohorts to study common cardio-metabolic 321 
markers in the adult offspring of mothers with GDM or overweight/obesity at start of 322 
pregnancy. There are two main findings in this study. First, maternal GDM was associated 323 
with increased insulin resistance and risk for an atherogenic lipid profile in adult offspring. 324 
Some, but not all, of this association was explained by confounding factors or current 325 
offspring characteristics including adiposity. Second, in offspring of mothers with pre-326 
pregnancy overweight/obesity without GDM the consequences were not as clear. They had 327 
higher fasting glucose and insulin than controls, in part explained by parental and prenatal 328 
confounders or adult BMI or body fat percentage, but similar levels of other cardio-329 
metabolic markers. This pattern differs from that of body composition. In this same cohort 330 
exposure to both maternal GDM and overweight/obesity was associated with higher 331 
offspring fat percentage and waist circumference, with stronger associations found related 332 
to maternal overweight/obesity (11). 333 
Our findings of higher fasting glucose and insulin in OGDM compared with controls, 334 
attenuated to non-significance after adjusting for confounders and current characteristics. 335 
To further differentiate between the effects of maternal GDM and maternal 336 
overweight/obesity on offspring cardio-metabolic health, we divided OGDM participants 337 
into two subgroups based on maternal pre-pregnancy weight (BMI < 25 kg/m2 and BMI ≥ 25 338 
kg/m2). A combination of maternal GDM and overweight/obesity showed a greater effect on 339 
fasting glucose and insulin than maternal overweight/obesity alone. In the fully adjusted 340 
model, the adjustments attenuated these differences in fasting glucose and insulin; this 341 
attenuation was largely due to offspring BMI as a mediator in OGDM with maternal BMI ≥ 342 
25 kg/m2. 343 
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Further, we report an atherogenic lipid profile in OGDM vs. controls, based on lower HDL-C 344 
and ApoA1 in OGDM. ApoA1 is a major component of HDL-C and low levels of ApoA1 are a 345 
well established risk factor of atherosclerosis. 346 
In addition to the commonly measured indicators, we found lower SHGB in both OGDM-347 
men and OGDM-women. SHBG is a measure of insulin resistance and hyperandrogenism, 348 
and this may reflect increased cardio-metabolic risk later in life. 349 
Traditionally, the global obesity epidemic has been explained by an increase in availability 350 
and consumption of energy-dense foods and a simultaneous reduction in physical activity. 351 
However, other factors behind this rise in obesity prevalence exist, including genetic factors, 352 
an adverse intrauterine milieu and epigenetic changes this milieu may provoke (2). GDM is a 353 
common cause of such an adverse milieu and may cause epigenetic changes in offspring. For 354 
instance, in a GDM mice model, offspring exposed to GDM showed altered DNA methylation 355 
patterns in the pancreas, and this phenotype was characterized by dyslipidemia, insulin 356 
resistance and glucose intolerance (3). Our findings suggest that maternal GDM and pre-357 
pregnancy overweight without diagnosed GDM may have distinct effects on offspring 358 
health. Previous studies have shown robust associations between higher maternal pre-359 
pregnancy BMI and offspring adiposity as indicated by increased fat mass, fat-free mass and 360 
percentage of body fat in both neonates (8), and 6-7 year old children (9); higher BMI and 361 
greater waist circumference at adolescence (10), higher BMI, waist circumference, fat mass 362 
and fat percentage in young adulthood (11) and higher fat mass and BMI at older age (12). 363 
As for pre-pregnancy BMI and offspring cardio-metabolic risk factors, Gaillard et al reported 364 
an adverse cardio-metabolic profile (including lipid levels, glucose, insulin, homeostatic 365 
model assessment of insulin resistance) in 1392 adolescents at mean age 17 years (21). 366 
These associations were independent of maternal GDM and largely mediated by adolescent 367 
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BMI. In another study, including 1400 participants at 32 years of age, higher maternal pre-368 
pregnancy BMI was associated with higher offspring blood pressure, insulin and triglycerides 369 
and lower HDL-C (22), again independent of maternal GDM and fully explained by current 370 
BMI of the offspring. This is consistent with our finding of higher fasting glucose and insulin 371 
among ONO who, however, had similar serum lipids and other biomarkers as controls. 372 
As to offspring of mothers with GDM, a previous study in 16-year-olds, in one of our source 373 
cohorts, showed that they have a higher BMI and waist circumference at adolescence than 374 
offspring of mothers without GDM (4). Further, in that study fasting insulin was higher and 375 
homeostatic model assessment-insulin sensitivity was lower in offspring to mothers with 376 
GDM, while blood lipids and glucose where similar to controls. To some extent maternal 377 
GDM is also associated with adult offspring body composition. In the same cohort 378 
participants, in which we now report on cardio-metabolic markers in the current study, 379 
higher fat percentages were seen in offspring exposed to GDM (11). As for maternal 380 
diabetes and offspring cardio-metabolic risk factors at adult age; recently a large Canadian 381 
cohort study including 467 850 mother-infant dyads, described an association between both 382 
maternal type 2 diabetes (T2D) during pregnancy and GDM with T2D in offspring by age 30 383 
(23). In this study exposure to maternal T2D during pregnancy conferred a greater risk to 384 
offspring compared with GDM exposure (3.19 vs. 0.80 cases of T2D per 1000 person-years) 385 
(23). In line with the Canadian study, we also showed increased markers of insulin 386 
resistance, i.e. higher fasting insulin and lower SHBG, HDL-C and ApoA1, in offspring with 387 
prenatal exposure to maternal GDM as compared to controls. 388 
Recently, Bellatorre et al reported an increase in liver fat, independent of offspring 389 
adiposity, in both childhood (mean age 10.4 years) and adolescence (mean age 16.4 years) 390 
in offspring of mothers with pre-pregnancy obesity (BMI ≥ 30 kg/m2), while no such effect 391 
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was found in offspring of mothers with GDM (24). In our study we did not find any 392 
associations between GDM or maternal pre-pregnancy overweight/obesity and  393 
biochemical markers of increased liver fat; levels of offspring liver enzymes were similar 394 
between groups. 395 
Strengths of our study include a rather large sample size and long follow-up time. One of the 396 
indications for screening GDM was having a pre-pregnancy BMI ≥ 25 kg/m2, thus mothers 397 
with GDM could be reliably separated from our group of normoglycemic mothers with 398 
overweight/obesity. To further distinguish between the effects of maternal GDM and 399 
maternal overweight/obesity on offspring cardio-metabolic health, we reran all analyses 400 
with OGDM participants further divided into two subgroups based on maternal pre-401 
pregnancy weight (BMI < 25 kg/m2 and BMI ≥ 25 kg/m2 vs. controls). In these subgroup 402 
analyses with diminished numbers of participants, our results remained similar. Our 403 
participants come from an ethnically homogenous Finnish population, combined from two 404 
longitudinal study cohorts. The homogeneity of our study population may decrease the 405 
generalizability of our findings. Further, in the analyses we adjusted for important 406 
confounders, including perinatal and pregnancy related factors, parental hypertension, 407 
diabetes, stroke and myocardial infarction, and current participant related factors. However, 408 
residual confounding remains possible. Both treatment and GDM screening guidelines have 409 
changed during the previous 25 years. This may have introduced bias, depending on the 410 
adequacy of the screening. Thus, the GDM offspring in the current study may represent a 411 
more severe end of the GDM spectrum in today’s pregnant women. Unfortunately, we do 412 
not have data on maternal glucose levels throughout pregnancy. 413 
 414 
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In sum, we found that maternal GDM is associated with increased levels of insulin resistance 415 
and a more atherogenic lipid profile in young adult offspring, as compared with controls. 416 
These findings suggest increased risk of cardio-metabolic diseases later in life. Maternal pre-417 
pregnancy overweight or obesity alone was associated with offspring insulin resistance, but 418 
the association was weaker and explained by current adiposity. 419 
  420 
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